Drug Trial Radar · NCT06316791
Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases
Last checked: Nov 19, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Dec 14, 2021
Primary completion
Dec 13, 2025
Study completion Dec 13, 2025
Sponsor
- Lead sponsor
- Juventas Cell Therapy Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 18, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Exploratory clinical study of CNCT19 anti CD19 cell therapy in the treatment of refractory autoimmune diseases,To evaluate the safety and tolerability of CNCT19 in patients with refractory systemic lupus erythematosus (lupus nephritis, immune thrombocytopenia), refractory ANCA-associated vasculitis, and refractory dermatomyositis on the basis of standard of care.
Conditions
- Lupus Erythematosus, Systemic
Interventions
single dose of CNCT19Biological
Autologous 2nd generation CD19-directed CAR-T cells, infusion intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Experiencing Treatment-Emergent Adverse Events(TEAE)Time frame: Up to 1 year after CNCT19 infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.